NUCLEIC ACIDS, PROTEIN SYNTHESIS, AND MOLECULAR GENETICS
The Putative Cofactor TIF1α Is a Protein Kinase That Is Hyperphosphorylated upon Interaction with Liganded Nuclear Receptors*

https://doi.org/10.1074/jbc.273.26.16199Get rights and content
Under a Creative Commons license
open access

Ligand-induced gene activation by nuclear receptors (NRs) is a complex process requiring dissociation of corepressors and recruitment of coactivators. The putative transcriptional intermediary factor TIF1α has been previously characterized as a nuclear protein that interacts directly with the AF-2 ligand-dependent activating domain present in the ligand-binding domain of numerous steroid and nonsteroid receptors, including the estrogen (ERα) and retinoid X (RXRα) receptors. We report here that TIF1α is both a phosphoprotein and a protein kinase. TIF1α coexpressed in COS-1 cells with RXRα or ERα is phosphorylated and becomes hyperphosphorylated upon ligand treatment. This hyperphosphorylation requires the binding of TIF1α to transcriptionally active NRs since it is prevented by mutations either in the core (α-helix 12 of the ligand-binding domain) of the AF-2 activating domains of RXRα and ERα or in the NR box of TIF1α that are known to prevent TIF1α-NR interactions. Thus, TIF1α is a phosphoprotein that undergoes ligand-dependent hyperphosphorylation as a consequence of nuclear receptor binding. We further show that purified recombinant TIF1α possesses intrinsic kinase activity and that, in addition to autophosphorylation, TIF1α selectively phosphorylates the transcription factors TFIIEα, TAFII28, and TAFII55 in vitro. These latter results raise the possibility that TIF1α may act, at least in part, by phosphorylating and modifying the activity of components of the transcriptional machinery.

Cited by (0)

*

This work was supported in part by CNRS, INSERM, the Hôpital Universitaire de Strasbourg, the Collège de France, the Association pour la Recherche sur le Cancer, the Fondation pour la Recherche Médicale, the Ligue Nationale contre le Cancer, and the Human Frontier Science Program. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Present address: Synthélabo Recherche, 10 rue des Carrierés, 97500 Rueil-Malmaison, France.

§

Present address: Novo Nordisk A/S, Novo Allé, DK-2880 Bagsraerd, Denmark.

These authors contributed equally to this work.

Supported by the Ministère de la Recherche et de l'Enseignement Supérieur.

**

Present address: Université de Rennes 1, Faculté de Médecine, CNRS UPR 41, 2 avenue du Professeur Léon Bernard, 35043 Rennes Cedex, France.